The Bladder Utility Symptom Scale (BUSS): A Novel Patient-Reported Outcome Instrument in Bladder Cancer.
J Urol. 2018 Mar 09;:
Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Urol Oncol. 2018 Feb 14;:
J Dent Child (Chic). 2016 Sep 15;83(3):125-131
J Clin Oncol. 2017 Dec 20;:JCO2017761064
Defining a cohort of men who may not require repeat prostate biopsy based on PCA3 score and MRI: The dual negative effect.
J Urol. 2017 Nov 23;:
What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?
Can Urol Assoc J. 2017 Mar-Apr;11(3-4):118-122
Science. 2017 Apr 28;356(6336):418-422
Urol Oncol. 2017 Jan 03;:
Development and External Validation of a Biopsy-Derived Nomogram to Predict Risk of Ipsilateral Extraprostatic Extension.
BJU Int. 2016 Dec 08;: